The impact of frailty syndrome on humoral response to SARS-CoV-2 mRNA vaccines in older kidney transplant recipients.
Frailty
Kidney transplantation
SARS-CoV-2 infection
Vaccination
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
01
11
2022
accepted:
11
03
2023
medline:
23
10
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
Advanced age is associated with an impaired humoral immune response to SARS-CoV-2 mRNA vaccination in kidney transplant recipients (KTR). The mechanisms are, however, poorly understood. Frailty syndrome assessment may determine the most vulnerable population. This study is a secondary analysis of a prospective study (NCT04832841) regarding seroconversion after BNT162b2 vaccination, including 101 SARS-CoV-2 naïve KTR 70 years and older. The Fried frailty components were evaluated, and antibodies against S1 and S2 subunits of SARS-CoV-2 were examined > 14 days after the second dose of BNT162b2 vaccine. Seroconversion was observed in 33 KTR. Male gender, eGFR, MMF-free immunosuppression, and a lower frailty score were associated with higher seroconversion rates in univariable regression. Concerning frailty components, physical inactivity had the most negative effect on seroconversion (OR = 0.36, 95% CI 0.14-0.95, p = 0.039). In a multivariable regression adjusted for eGFR, MMF-free immunosuppression, time from transplant and gender, pre-frail (OR = 0.27, 95% CI 0.07-1.00, p = 0.050), and frail status (OR = 0.14, 95% CI 0.03-0.73, p = 0.019) were associated with an increased risk of unresponsiveness to SARS-CoV-2 vaccines. Frailty was associated with an impaired humoral response to SARS-CoV-2 mRNA vaccination in older SARS-CoV-2 naïve KTR. This study is registered under the identifier NCT04832841 on ClinicalTrials.gov.
Identifiants
pubmed: 37027078
doi: 10.1007/s11255-023-03557-6
pii: 10.1007/s11255-023-03557-6
pmc: PMC10081301
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
0
RNA, Messenger
0
Antibodies, Viral
0
Banques de données
ClinicalTrials.gov
['NCT04832841']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2959-2965Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NV19-06-00031
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NU22-C-126
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NU21-06-00021
Informations de copyright
© 2023. The Author(s).
Références
J Sports Med Phys Fitness. 2003 Sep;43(3):404
pubmed: 14625524
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
BMC Public Health. 2021 Aug 6;21(1):1521
pubmed: 34362319
N Engl J Med. 2021 Aug 19;385(8):729-743
pubmed: 34407344
Aging (Albany NY). 2020 Dec 9;12(24):24633-24650
pubmed: 33347425
Transplant Direct. 2021 Dec 23;8(1):e1248
pubmed: 34966837
Transplantation. 2022 Apr 1;106(4):842-852
pubmed: 34999659
Vaccine. 2011 Jul 12;29(31):5015-21
pubmed: 21565245
Am J Transplant. 2021 Dec;21(12):3926-3935
pubmed: 34212497
Kidney Int. 2021 Jun;99(6):1498-1500
pubmed: 33887315
J Am Geriatr Soc. 2021 Jun;69(6):1441-1447
pubmed: 33768521
Transplantation. 2017 Sep;101(9):2126-2132
pubmed: 27779573
Open Forum Infect Dis. 2020 Apr 24;7(5):ofaa148
pubmed: 32500087
J Gerontol A Biol Sci Med Sci. 2022 Dec 29;77(12):2474-2481
pubmed: 35184167
Brain Behav Immun. 2007 Feb;21(2):209-17
pubmed: 16824730
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337
Transplantation. 2015 Apr;99(4):805-10
pubmed: 25393156
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Hum Vaccin Immunother. 2018 Feb 1;14(2):361-367
pubmed: 29172948
Am J Transplant. 2013 Aug;13(8):2091-5
pubmed: 23731461
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Front Immunol. 2021 Nov 16;12:778679
pubmed: 34868051